Gain Therapeutics To Participate in Upcoming Investor Conferences

Rhea-AI Summary

Gain Therapeutics (Nasdaq: GANX), a clinical-stage biotechnology company focused on developing next-generation allosteric small molecule therapies, has announced its participation in two major investor conferences in February 2025.

CEO Gene Mack will deliver corporate presentations at:

• The BIO CEO & Investor Conference on February 11 at 1:15pm ET in the Plymouth Room at The New York Marriott Marquis
• The Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12 at 10:40am ET (virtual presentation)

Registered attendees can schedule one-on-one meetings with Gain management through the respective conference platforms. Investors unable to attend can request meetings by contacting ir@gaintherapeutics.com.

BETHESDA, Md., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, Chief Executive Officer of Gain, will present at two upcoming investor conferences:

• BIO CEO & Investor Conference on Tuesday, February 11, at 1:15pm ET
  • Gene Mack will give a corporate presentation at the Plymouth Room, The New York Marriott Marquis. Registered conference attendees may schedule one-on-one meetings with Gain management via the conference scheduling platform.
• Oppenheimer 35^th Annual Healthcare Life Sciences Conference on Wednesday, February 12, at 10:40am ET
  • Gene Mack will give a virtual corporate presentation. Interested investors are encouraged to contact their Oppenheimer representative to schedule one-on-one meetings with Gain management.

If you are unable to attend the conferences and would like to schedule a meeting with Gain management, please contact ir@gaintherapeutics.com.

About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate, GT-02287 is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation. Results from a Phase 1 study of GT-02287 in healthy volunteers demonstrated favorable safety and tolerability, plasma exposure in the projected therapeutic range, CNS exposure, and target engagement and modulation of GCase enzyme.

Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced Magellan™ platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.

Forward-Looking Statements
This release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. These forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, statements regarding: the development of the Company’s current or future product candidates including GT-02287; expectations regarding the timing of results from a Phase 1b clinical study for GT-02287; expectations regarding the timing of patient enrollment for a Phase 1b clinical study for GT-02287; and the potential therapeutic and clinical benefits of the Company’s product candidates. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, please refer to the Company’s Form 10-K for the year ended December 31, 2023 and Form 10-Q for the quarter ended September 30, 2024. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contacts:
Apaar Jammu and Chuck Padala
ajammu@gaintherapeutics.com
chuck@lifesciadvisors.com

Media Contacts:
Russo Partners
Nic Johnson and Elio Ambrosio
nic.johnson@russopartnersllc.com
elio.ambrosio@russopartnersllc.com
(760) 846-9256

FAQ

When and where will GANX present at the BIO CEO & Investor Conference 2025?

Gain Therapeutics (GANX) will present on Tuesday, February 11, 2025, at 1:15pm ET in the Plymouth Room at The New York Marriott Marquis.

What time is GANX's presentation at the Oppenheimer Healthcare Conference 2025?

Gain Therapeutics will present virtually at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12, 2025, at 10:40am ET.

How can investors schedule meetings with GANX management at these conferences?

Registered conference attendees can schedule meetings through the conference platforms. Those unable to attend can email ir@gaintherapeutics.com to arrange meetings.

What type of therapeutic solutions is GANX developing?

Gain Therapeutics is developing next-generation allosteric small molecule therapies as a clinical-stage biotechnology company.